19 completed, 2 terminated, 1 active not recruiting, 1 recruiting. 24 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 24 | Completed 19, Terminated 2, Active not recruiting 1, Recruiting 1, Unknown 1 |
| Phase 2 | 3 | Completed 3 |
Follow R-Pharm: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI RPH-030, Vectibix®, Irinotecan - Metastatic Colorectal Cancer | Phase 1 | Recruiting | R-Pharm | 180 | 2025-04-17 | 2026-04-22 |
| A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With Exacerbations RPH-035, Ocrevus® - Multiple Sclerosis | Phase 1 | Active not recruiting | R-Pharm | 180 | 2025-04-16 | 2026-07-14 |
| Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms RPH-075, Keytruda® - Skin Melanoma, Squamous Non-small-cell Lung Cancer | Phase 1 | Completed | R-Pharm | 90 | 2023-03-01 | 2026-07-15 |
| Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19 AZD1222, rAd26-S - COVID-19 | Phase 1 / Phase 2 | Completed | R-Pharm | 100 | 2021-09-15 | 2022-06-03 |
| Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19) AZD1222, rAd26-S - COVID-19 | Phase 1 / Phase 2 | Completed | R-Pharm | 100 | 2021-07-13 | 2022-10-26 |
| A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma RPH-002, Erbitux®, cisplatin - Head and Neck Squamous Cell Carcinoma | Phase 1 | Completed | R-Pharm | 118 | 2020-06-15 | 2026-07-14 |
| Pharmacokinetic Equivalence and Safety Study of RPH-001 and Avastin® RPH-001, Avastin - Healthy | Phase 1 | Completed | R-Pharm | 80 | 2018-07-10 | 2019-02-05 |
| A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs Narlaprevir, Ritonavir, Tenofovir Disoproxil Fumarate - Healthy | Phase 1 | Completed | R-Pharm | 36 | 2017-04-24 | 2019-02-19 |
| Pharmacokinetics and Pharmacodynamics of RPH-104 in Healthy Subjects RPH-104, Sodium chloride Sterile Injection 0.9% w/v - Healthy | Phase 1 | Completed | R-Pharm | 35 | 2016-01-01 | 2021-12-28 |
| A Pharmacokinetic Study of Narlaprevir as a Single Dose or With Ritonavir Combination in Patients With Hepatic Impairment and Healthy Matched Volunteers Narlaprevir, Ritonavir - Hepatic Impairment | Phase 1 | Completed | R-Pharm | 32 | 2013-11-08 | 2019-05-22 |
| Phase I Combination Ixabepilone + Cisplatin Ixabepilone, Cisplatin - Non Small Cell Lung Cancer | Phase 1 | Completed | R-Pharm | 30 | 2009-05-01 | 2020-10-28 |
| Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg, Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg, Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg - Locally Advanced or Metastatic Breast Cancer | Phase 1 | Terminated | R-Pharm | 13 | 2008-06-01 | 2016-03-10 |
| Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer Ixabepilone, 32 mg/m^2 + Carboplatin, 5 mg/min/mL, Ixabepilone, 32 mg/m^2 + Carboplatin, 6 mg/min/mL - Non-small Cell Lung Cancer (NSCLC) | Phase 1 | Completed | R-Pharm | 12 | 2008-06-01 | 2016-03-10 |
| Phase 1 Trial of Oral Ixabepilone Ixabepilone (oral formulation) - Advanced Solid Tumors | Phase 1 | Terminated | R-Pharm | 23 | 2008-05-01 | 2016-03-10 |
| A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer Ixabepilone, Capecitabine - Breast Cancer | Phase 1 | Completed | R-Pharm | 9 | 2008-02-01 | 2016-03-10 |
| A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer Ixabepilone, 5 mg/d, Ixabepilone, 10 mg/d, Ixabepilone, 15 mg/d - Cancer | Phase 1 | Completed | R-Pharm | 40 | 2007-01-01 | 2016-03-10 |
| Phase I Combination w/ Epirubicin Ixabepilone, Epirubicin - Metastatic Breast Cancer | Phase 1 | Completed | R-Pharm | 42 | 2006-08-01 | 2016-03-10 |
| Ixabepilone Administered as an Enteric Coated Formulation. Ixabepilone - Cancer | Phase 1 / Phase 2 | Completed | R-Pharm | 30 | 2006-04-01 | 2017-01-30 |
| Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer ixabepilone, Rifampin - Advanced Solid Tumors, Neoplasms | Phase 1 | Completed | R-Pharm | 19 | 2005-09-01 | 2020-11-02 |
| Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies. Ixabepilone - Solid Malignancies | Phase 1 | Completed | R-Pharm | 35 | 2005-09-01 | 2020-11-02 |
Showing 20 of 24. Sign in to see all of them.
Neoplasms (6) · Breast Neoplasms (4) · COVID-19 (2) · Carcinoma, Non-Small-Cell Lung (2) · Lung Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Bronchiolitis Obliterans Syndrome (1) · Carcinoma (1) · Coinfection (1) · Colorectal Neoplasms (1) · Coronavirus Infections (1) · Hepatitis C (1) · Lung Diseases (1) · Melanoma (1) · Multiple Sclerosis (1)
ixabepilone (14) · Capecitabine (4) · ChAdOx1 nCoV-19 (2) · Cisplatin (2) · Ritonavir (2) · narlaprevir (2) · Bevacizumab (1) · Carboplatin (1) · Cetuximab (1) · Docetaxel (1) · Dosage Forms (1) · Epirubicin (1) · Epothilones (1) · Famotidine (1) · Fluorouracil (1)
United States (10) · Russia (8) · Italy (3) · Japan (2) · Australia (1) · France (1) · Georgia (1) · Turkey (Türkiye) (1) · United Arab Emirates (1)
Mikhail Samsonov (9) · David R. Spriggs, MD (1) · Linnea Chap, MD (1) · Sibel Goksel, MD, PhD (1)
2008 (1)